CJC-1295 + Ipamorelin (blend or stack)
Also called CJC/Ipa
One of the most discussed growth hormone pairings, sold both premixed (usually no-DAC CJC-1295) and as separate vials (often DAC CJC-1295). Neither the blend nor the stack has been tested in a human trial.
Overview
What it is
CJC-1295 (no DAC or with DAC) plus ipamorelin. The DAC and no-DAC forms are different substances; check which one a product contains.
How it works
CJC-1295 acts on the GHRH receptor and ipamorelin on the ghrelin receptor, so they stimulate growth hormone through two complementary pathways.
What the research shows
CJC-1295 with DAC raised growth hormone and IGF-1 in healthy adults. Ipamorelin raised growth hormone briefly in healthy men and was studied after bowel surgery without a significant benefit. No human study tested the combination.
Studied for
- Growth hormone releaseingredients separately
Safety and regulatory status
Safety and side effects
Reported effects with growth-hormone-raising compounds include water retention, headache, tingling or numbness, flushing and injection-site reactions. FDA flags both ingredients for immune and impurity concerns.
Regulatory status
Not FDA approved. Both are prohibited in sport.
Mixing and dosing reference
Reference information only. Read before using this section.
CJC-1295 NO DAC + Ipamorelin (10 mg Blend) Dosage Protocol
- Vial
- 10 mg total blend 5 mg CJC-1295 NO DAC + 5 mg Ipamorelin
- Add diluent
- 3 mL
- Concentration
- 3.33 mg/mL
- 1 unit (U-100)
- 33.33 mcg total in 0.01 mL
- Route
- Subcutaneous
- How often
- Once per day (subcutaneous).
- Typical range
- 100–300 mcg of each peptide once daily (gradual titration).
- Cycle length
- 8–12 weeks; optional extension to 16 weeks.
Standard / Gradual Approach
| Week | Daily Dose (mcg each) | Units (per injection) (mL) |
|---|---|---|
| Weeks 1–2 | 100 mcg each | 3 units (0.03 mL) |
| Weeks 3–4 | 150 mcg each | 4.5 units (0.045 mL) |
| Weeks 5–6 | 200 mcg each | 6 units (0.06 mL) |
| Weeks 7–12 | 250–300 mcg each | 7.5–9 units (0.075–0.09 mL) |
How to mix
- Draw 3.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming.
- Gently swirl/roll until dissolved (do not shake).
- Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
Dosing details
- Start: 100 mcg each peptide daily; increase by ~50 mcg every 1–2 weeks as tolerated.
- Target: 200–300 mcg each peptide daily by Weeks 5–12.
- Frequency: Once per day (subcutaneous).
- Cycle Length: 8–12 weeks; optional extension to 16 weeks.
- Timing: Typically before bed or upon waking; rotate injection sites.
Storage
- Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; minimize moisture exposure.
- Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); follow product-specific use-by instructions; avoid freeze–thaw.
- Allow vials to reach room temperature before opening to reduce condensation uptake.
Administration technique
- Clean the vial stopper and skin with alcohol; allow to dry.
- Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue.
- Do not aspirate for subcutaneous injections; inject slowly and steadily.
- Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy.
Important notes
- Use new sterile insulin syringes; dispose in a sharps container.
- Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation.
- Inject slowly; wait a few seconds before withdrawing the needle.
- Document daily dose and site rotation to maintain consistency.
- For doses under 10 units, use 30- or 50-unit syringes for better precision.
Protocol source: PeptideDosages.com
Common questions
Is the blend the same as the stack?
No. Blends usually use no-DAC CJC-1295 in one vial; stacks use separate vials, often with DAC.
Does ipamorelin avoid raising cortisol?
Animal studies suggested minimal cortisol effect; that is not guaranteed in people.
Related in Performance and Recovery
Sources and further reading (4)
- Teichman SL, et al. CJC-1295 in healthy adults. JCEM, 2006.
- Raun K, et al. Ipamorelin, the first selective GH secretagogue, 1998.
- FDA. CJC-1295 and ipamorelin evaluations, 2024.
- Source summary: PeptideDosages.com research overview (rewritten for NVO).
Laboratory research material: CJC + Ipamorelin Research Use Only